Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

UPenn Observational Research Repository on Neurodegenerative Disease (UNICORN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04715399
Recruitment Status : Recruiting
First Posted : January 20, 2021
Last Update Posted : January 20, 2021
Sponsor:
Collaborators:
National Institutes of Health (NIH)
Alzheimer's Association
United States Department of Defense
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Murray Grossman, University of Pennsylvania

Brief Summary:
The aim of this study is to create a repository of both cross-sectional and longitudinal data, including cognitive, linguistic, imaging and biofluid biological specimens, for neurodegenerative disease research and treatment.

Condition or disease Intervention/treatment
Frontotemporal Degeneration(FTD) Primary Progressive Aphasia(PPA) Familial Frontotemporal Lobar Degeneration (fFTLD) Amyotrophic Lateral Sclerosis(ALS) Lewy Body Disease(LBD) Progressive Supranuclear Palsy(PSP) Corticobasal Syndrome(CBS) Posterior Cortical Atrophy(PCA) Alzheimer's Disease(AD) Other: No intervention

Detailed Description:
The Principal Investigator (PI) at the University of Pennsylvania seeks to better understand neurodegenerative diseases and is continually expanding research efforts and collaborations regarding the factors which may contribute to these illnesses. Investigators seek to better understand the basis of neurodegenerative conditions by creating a multimodal repository, including: clinical data such as demographic characteristics, vital signs and motor scales; cognitive and speech data; neuroimaging data; and biological specimens with associated biofluid biomarkers and genetic data. Investigators pursue acquiring these data from neurodegenerative disease patients, people at risk for neurodegenerative disease due to a family history, and unaffected adults. Targeted conditions include frontotemporal degeneration (FTD), primary progressive aphasia PPA), amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), familial frontotemporal lobar degeneration (fFTLD), non-amnestic variants of Alzheimer's disease including logopenic progressive aphasia and posterior cortical atrophy, and Lewy body disease. This study aims to collect clinical and cognitive data, imaging data, and biospecimen samples from people whose background can inform research and treatment for neurodegenerative diseases, and make these samples and data available to qualified researchers at the University of Pennsylvania and collaborating academic centers and industry partners.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: University of Pennsylvania Centralized Observational Research Repository on Neurodegenerative Disease (UNICORN)
Actual Study Start Date : May 29, 2020
Estimated Primary Completion Date : May 30, 2070
Estimated Study Completion Date : May 30, 2070


Group/Cohort Intervention/treatment
Cross-sectional Other: No intervention
No intervention

Longitudinal Other: No intervention
No intervention




Primary Outcome Measures :
  1. Status of progression - changes in neuropsychological tests. [ Time Frame: This is a natural history study-participants are followed from date of enrollment until death, withdraw, or funding is no longer available, or until 600 months have passed. ]
    The changes of neuropsychological tests (well known cognitive measures such as: Naming test, CVLT, MoCA, Oral Trails, etc.) in neurodegenerative diseases over time.


Secondary Outcome Measures :
  1. Status of progression - changes in language processing. [ Time Frame: This is a natural history study-participants are followed from date of enrollment until death, withdraw, or funding is no longer available, or until 600 months have passed. ]
    The effect of changes in language processing (effortful speech) as categorized by impaired semantic memory in neurodegenerative diseases over time.

  2. Status of progression - changes in social disinhibition. [ Time Frame: This is a natural history study-participants are followed from date of enrollment until death, withdraw, or funding is no longer available, or until 600 months have passed. ]
    The effect of changes in social behavioral testing, which categorized by rule violation (social disinhibition) progression in neurodegenerative diseases over time.

  3. Status of progression - changes in biofluids. [ Time Frame: This is a natural history study-participants are followed from date of enrollment until death, withdraw, or funding is no longer available, or until 600 months have passed. ]
    The change of disease status as categorized by biomarkers in biofluids in neurodegenerative diseases over time.

  4. Status of progression -changes in Neuroimaging [ Time Frame: This is a natural history study-participants are followed from date of enrollment until death, withdraw, or funding is no longer available, or until 600 months have passed. ]
    The progressive changes of images in multimodal neuroimaging techniques in neurodegenerative diseases over time.


Biospecimen Retention:   Samples With DNA
Blood samples, cerebrospinal fluid (CSF) samples, and saliva or buccal samples may be taken and stored for DNA, RNA and protein extraction and analysis at the University of Pennsylvania and/or research collaborators elsewhere.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
To better understand neurodegenerative diseases, the investigators will include people living with these illnesses, people at risk of developing these illnesses, and people without neurodegenerative disease who wish to contribute to science as controls.
Criteria

Inclusion Criteria:

This protocol will include 3 groups of people:

  1. People with a clinical diagnosis of a neurodegenerative disease. such as frontotemporal degeneration(FTD), primary progressive aphasia(PPA), Lewy body disease(LBD), amyotrophic lateral sclerosis(ALS), progressive supranuclear palsy(PSP), corticobasal syndrome(CBS), posterior cortical atrophy(PCA), Alzheimer's disease(AD), Parkinson's disease(PD)
  2. People with a family history of neurodegenerative disease who may or may not be symptomatic, and may or may not be mutation carriers such as familial frontotemporal lobar degeneration (fFTLD) or familial ALS,
  3. People with no known neurological disease who will provide control data.

Exclusion Criteria:

  • Anyone who is under the age of 18.
  • Anyone with a condition or in a situation which, in the Investigator's opinion, could confound the study findings or may interfere significantly with a person's participation, including but not limited to neurological, psychological and other medical conditions (such as cardiac, neurosurgical, infectious conditions).
  • Individual participants may be excluded from some, but not all, study procedures for safety reasons when they have a contraindication or at the discretion of the Investigator. For example, persons with metal implants which are not MRI-safe will not be able to take part in imaging, and those on blood thinning medications may not be able to take part in lumbar puncture.
  • Pregnant women; if a woman becomes pregnant during the study, research activities that may increase risk to the patient and the unborn fetus will be stopped until the end of pregnancy, at which point participation can be resumed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04715399


Contacts
Layout table for location contacts
Contact: Wei Xu 2153495863 weixu@pennmedicine.upenn.edu
Contact: Gabriela Bustamante 2156623361 gabriela.bustamante@pennmedicine.upenn.edu

Locations
Layout table for location information
United States, Pennsylvania
University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Wei Xu, MD, MBE    215-349-5863    weixu@pennmedicine.upenn.edu   
Contact: Gabriela Bustamante, BSN, RN    2156623361    gabriela.bustamante@pennmedicine.upenn.edu   
Sponsors and Collaborators
University of Pennsylvania
National Institutes of Health (NIH)
Alzheimer's Association
United States Department of Defense
National Institute on Aging (NIA)
Investigators
Layout table for investigator information
Principal Investigator: Murray Grossman, MD University of Pennsylvania
Layout table for additonal information
Responsible Party: Murray Grossman, Professor; Director, Penn FTD Center; Chief, Cognitive Neurology Division, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT04715399    
Other Study ID Numbers: 842873
P01AG017586 ( U.S. NIH Grant/Contract )
R01AG054519 ( U.S. NIH Grant/Contract )
P01AG066597 ( U.S. NIH Grant/Contract )
First Posted: January 20, 2021    Key Record Dates
Last Update Posted: January 20, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Information about study participants will be kept confidential and managed according to the requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Only deidentified data will be shared. We will not share individual participant identifiable data with other researchers outside of the institution, unless the participant allows us to by signing a separate data release form.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Alzheimer Disease
Aphasia
Neurodegenerative Diseases
Supranuclear Palsy, Progressive
Aphasia, Primary Progressive
Pick Disease of the Brain
Frontotemporal Dementia
Lewy Body Disease
Frontotemporal Lobar Degeneration
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurocognitive Disorders
Mental Disorders
Neuromuscular Diseases
Spinal Cord Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Speech Disorders
Language Disorders
Communication Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Basal Ganglia Diseases
Movement Disorders